Last reviewed · How we verify
Prostaglandin E2 (Propess)
Prostaglandin E2 (PGE2) binds to prostaglandin E receptors on uterine smooth muscle and cervical tissue to promote uterine contractions and cervical ripening.
Prostaglandin E2 (Propess) is a cervical ripening agent used in obstetrics. It is under investigation for various indications, including labor induction in term pregnancies. The drug has a strong clinical trial presence but lacks FDA approval. Safety concerns include common side effects like uterine hyperstimulation and fetal distress.
At a glance
| Generic name | Prostaglandin E2 (Propess) |
|---|---|
| Also known as | dinoprostone |
| Sponsor | University Medical Centre Maribor |
| Drug class | Prostaglandin E2 agonist |
| Target | Prostaglandin E receptors (EP1, EP2, EP3, EP4) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics |
| Phase | FDA-approved |
Mechanism of action
PGE2 is a naturally occurring eicosanoid that activates EP1, EP2, EP3, and EP4 receptors on myometrial and cervical cells. This receptor activation increases intracellular calcium and promotes myometrial contractions while simultaneously softening and dilating the cervix through remodeling of collagen and increased tissue compliance. The Propess formulation delivers PGE2 via a vaginal insert for sustained local release.
Approved indications
- Cervical ripening and induction of labor in pregnant women at or near term with a medical indication for labor induction
Common side effects
- Uterine hyperstimulation with fetal heart rate changes
- Vaginal pain or discomfort
- Fever
- Nausea
- Diarrhea
- Back pain